NR4A1 and breast carcinoma: These signatures are more precise than classical clinicopathological biomarkers, such as histological grade and immunohistochemical (IHC) assessment of Ki67 among patients with hormone receptor (HR) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (−) breast cancer [1].